Crinetics reports Q4 2022 net loss of $45M; paltusotine Phase 3 data expected 3Q23 and 1Q24

Crinetics Pharmaceuticals, Inc.

2022-FY EPS reported -$3.15 revenue$4,737,000

Net loss $45.0M for Q4 2022 vs $30.8M in Q4 2021; full-year net loss $163.9M vs $107.6M.
R&D expenses $37.0M in Q4 2022, up from $24.6M; full-year $130.2M vs $84.3M.
Cash, equivalents, and investments $334.4M as of Dec 31, 2022; company expects runway through 2024.
Paltusotine Phase 3 PATHFNDR-1 topline data expected 3Q23; PATHFNDR-2 data now expected 1Q24.
NDA submission for paltusotine in acromegaly planned for 2024 pending positive Phase 3 results.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Crinetics Pharmaceuticals, Inc. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Crinetics Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.